Clinical Trial

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

Study acronym: Oligo-PRESTO
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2025 (before its estimated June 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
INDICATION: Oligometastatic hormone-sensitive prostate cancer patients. METHODOLOGY: Open label, double arm, randomized 1:1, multicenter phase III study. PRIMARY OBJECTIVE: To assess the efficacy of ablative radiotherapy (SBRT applied to all oligometastases) administered to all gross tumor sites (metastases and prostate if applicable), in oligometastatic hormone-sensitive prostate cancer patients.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-10-02; most recent amendment 2025-06-21.
Status change: Recruiting → Active, Not Recruiting 2025-06-21
Status change: Suspended → Recruiting 2020-09-14
Status change: Not Yet Recruiting → Suspended 2020-04-20
Trial Details
NCT Number NCT04115007
Lead Sponsor UNICANCER
Conditions Oligometastatic Hormone Sensitive Prostate Cancer
Enrollment 550 participants
Start Date 2020-06-23
Primary Completion 2026-06-23 (estimated)
Study Completion 2031-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-06-26